Zoledronic acid - CAS 165800-06-6
Catalog number: 165800-06-6
Category: APIs
Molecular Formula:
C5H10N2P2·H2O
Molecular Weight:
290.1
COA:
Inquire
MSDS:
Inquire
1. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid
A. D. Anastasilakis & S. A. Polyzos & A. Gkiomisi & Z. G. Saridakis. Osteoporos Int (2015) 26:2521–2527
In head-to-head comparison studies in both treatment naïve and pre-treated with oral bisphosphonates women with postmenopausal osteoporosis, denosumab has been proven superior to all oral bisphosphonates, namely alendronate, risedronate, and ibandronate in terms of BMD increases and bone turnover reduction. A recent meta-analysis has concluded that denosumab increases BMD at the lumbar spine (LS) and total hip more than bisphosphonates, including zoledronic acid, the most potent representative of the class [1]. No study has directly compared denosumab and zoledronic acid to date in terms of BMD and bone turnover marker changes. We have recently reported that, in treatment naïve patients, denosumab increases serum levels of sclerostin, while zoledronic acid decreases them, implying a diverse effect onWnt signaling. No prior study has reported on the effect of denosumab on serum sclerostin levels in patients previously treated with zoledronic acid. Since zoledronic acid is more potent than other bisphosphonates, sequential treatment with denosumab might not have the skeletal effects the above studies showed in patients previously treated with oral bisphosphonates, mainly alendronate. The primary aim of this study was to compare the effect of denosumab and zoledronic acid on LS BMD in postmenopausal women with low bone mass previously treated with zoledronic acid for 1 year. Secondary aims were to compare their effect on bone turnover markers (procollagen type 1 N-terminal propeptide [P1NP] and C-terminal telopeptide of type 1 collagen [CTx]), and serum sclerostin and free soluble RANKL (sRANKL) levels.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 28120-03-8 Tymazoline Hydrochloride

Tymazoline Hydrochloride
(CAS: 28120-03-8)

Tymazoline, a nasal decongestant, acts as an antihistaminic and sympathomimetic that exhibits antihistamine and antibacterial effects in research.

CAS 91421-42-0 Rubitecan

Rubitecan
(CAS: 91421-42-0)

CAS 75330-75-5 Lovastatin

Lovastatin
(CAS: 75330-75-5)

CAS 34758-84-4 CERM3024

CERM3024
(CAS: 34758-84-4)

CERM3024 is a centrally acting cough suppressant.

CAS 110429-35-1 Paroxetine Hydrochloride

Paroxetine Hydrochloride
(CAS: 110429-35-1)

CAS 147403-03-0 Azilsartan

Azilsartan
(CAS: 147403-03-0)

CAS 4320-13-2 Thiazinamium chloride

Thiazinamium chloride
(CAS: 4320-13-2)

Thiazinamium chloride is a safe, potent and efficacious bronchodilator after aerosol administration, with a rapid onset and moderate duration of action in anima...

CAS 22298-29-9 Betamethasone 17-benzoate

Betamethasone 17-benzoate
(CAS: 22298-29-9)

Betamethasone 17-benzoate was found to be effective in reducing symptoms and shortening healing time but not in preventing recurrences.

Chemical Structure

CAS 165800-06-6 Zoledronic acid

Quick Inquiry

Verification code

Featured Items